MIR5007

Across TCGA pan-cancer cohorts, MIR5007 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated MIR5007 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR5007 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR5007 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

STAD, ACC, and ESCA are the cancer types where MIR5007 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	II,III,IV	0.168	0.583	<.001	81	view →
ACC	DFS	Tertile	All	0.098	0.674	<.001	45	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
PRAD	DFS	Tertile	All	0.120	0.935	<.001	18	view →
BRCA	OS	Tertile	III,IV	0.702	0.906	.025	12	view →
UCEC	DFS	Tertile	All	0.763	0.899	.018	12	view →
BLCA	OS	Tertile	III,IV	0.862	0.530	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MIR5007–STAD (OS)

Open the STAD breakdown →